Weekly Digest – June 2026 Weekly Digest – June 2026 30 May 2026: MediLink Therapeutics announces B7-H3 ADC YL201 met primary endpoint in phase 3 Nasopharyngeal carcinoma study MediLink Therapeutics has announced that its B7-H3-targeted ADC YL201, successfully met the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 04 June 2026: Stipple Bio enters multi-target license agreement with Lonza to advance precision oncology ADC therapies Stipple Bio has strengthened its position in the next wave of ADC innovation […]
Weekly Digest – June 2026 Weekly Digest – June 2026 01 June 2026: Mabion and KriSan Biotech sign letter of intent to explore ADC collaboration supporting strategic ambitions advanced Solid tumor study Mabion and KriSan Biotech have signed a Letter […]
Weekly Digest – June 2026 Weekly Digest – June 2026 29 May 2026: Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358 Ratio Therapeutics and PharmaLogic have expanded their manufacturing collaboration to support the clinical development […]
Weekly Digest – May 2026 Weekly Digest – May 2026 27 May 2026: U.S. FDA approves DECNUPAZ for adult patients with BPDCN, a rare aggressive Blood cancer AbbVie has secured U.S. FDA approval for DECNUPAZ in blastic plasmacytoid dendritic cell […]
Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: Datroway approved in the U.S. as first TROP2-directed ADC for 1L metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitors AstraZeneca and Daiichi Sankyo have secured U.S. FDA approval […]
Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: CHMP recommends EU approval of Enhertu for previously treated HER2-positive metastatic Solid tumours AstraZeneca and Daiichi Sankyo have received a positive CHMP opinion for Enhertu in previously […]
Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: Gilead receives CHMP positive opinion for Trodelvy in 1L metastatic TNBC patients ineligible for PD-(L)1 inhibitors Gilead has received a positive CHMP opinion for Trodelvy in the […]
Weekly Digest – May 2026 Weekly Digest – May 2026 25 May 2026: Sino Biopharmaceuticals CLDN18.2 ADC LM-302 granted Priority Review with China approval expected Sino Biopharmaceuticals CLDN18.2-targeted ADC LM-302 has entered China’s priority review pathway, positioning the asset for […]
Weekly Digest – May 2026 Weekly Digest – May 2026 26 May 2026: Adcendo and MSD partner to evaluate ADCE-T02 plus KEYTRUDA in phase 1b advanced Solid tumor study Adcendo has entered a clinical collaboration and supply agreement with MSD […]
